Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Medtronic (MDT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Scholar Rock Holding (SRRK) and Medtronic (MDT) with bullish sentiments.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Scholar Rock Holding (SRRK)
Jefferies analyst Amy Li maintained a Buy rating on Scholar Rock Holding today and set a price target of $57.00. The company’s shares closed last Wednesday at $49.63.
Li has an average return of
According to TipRanks.com, Li is ranked #11786 out of 12128 analysts.
Scholar Rock Holding has an analyst consensus of Strong Buy, with a price target consensus of $58.00, which is a 16.3% upside from current levels. In a report issued on March 19, Cantor Fitzgerald also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Medtronic (MDT)
In a report released today, Brandon Vazquez from William Blair maintained a Buy rating on Medtronic. The company’s shares closed last Wednesday at $86.04.
According to TipRanks.com, Vazquez is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Medtronic is a Moderate Buy with an average price target of $111.50, representing a 28.8% upside. In a report issued on March 20, TipRanks – PerPlexity also upgraded the stock to Buy with a $102.00 price target.
Read More on SRRK:
Disclaimer & DisclosureReport an Issue
- Scholar Rock price target raised to $57 from $54 at Jefferies
- De-Risked Regulatory Path and Manufacturing Readiness Underpin Buy Rating on Apitegromab
- Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!
- Scholar Rock price target raised to $58 from $51 at BofA
- Apitegromab: Strengthened Regulatory Position and Dual-Site Strategy De-Risk Approval and Commercialization
